BVI announced the US Food and Drug Administration (FDA) approved its Finevision HP trifocal intraocular lens (IOL). According to a company press release, the third-generation Finevision HP incorporates BVI’s proprietary POD platform and CoPODize technology, harmonizing light distribution and minimizing visual disturbances. Its double C-loop, 4-point haptic design supports long-term stability and precise centration in the capsular bag.
"This FDA approval marks a pivotal step in expanding our IOL portfolio in the United States, supporting our mission to deliver best-in-class visual outcomes for patients globally," said Shervin Korangy, president and CEO of BVI, in the press release.
According to the company, the US clinical study demonstrated the lens’s potential impact for US patients. “The Finevision HP trifocal IOL reflects innovation in optic design, and I’m pleased to have been part of the US study evaluating its performance," said Vance Thompson, MD, ophthalmologist and study investigator, in the press release. "This lens represents an important step forward in expanding advanced IOL choices for surgeons and their patients.”
BVI said it will methodically roll out availability over the coming year. Finevision HP will be showcased at the AAO Annual Meeting this week in Orlando, Florida.